Antigen Detection Technology And Biomarkers Discovery Strategies Rapidly Fuel Tuberculosis Biomarkers Market Growth, Finds Fact.MR

In 2020, the demand for tuberculosis biomarkers faced a minor decline due to the Covid-19 pandemic. As the condition is recovering in 2021, the market players are upgrading their business operations by adopting innovative ways that attracts customers to regain their earlier positions in the market.

In 2021, rising government initiatives and efforts to create awareness regarding proper checkup and medication for tuberculosis contributes to add lucrative progress.

At present, the prevalence of multidrug-resistant tuberculosis and deaths caused worldwide due to this is creating a strong urge for tuberculosis biomakers. Growing use of biomarkers in personalised medicines as well as drug discovery & development is acting as a key trend favouring the growth.

For detailed insights on enhancing your product footprint, request for a sample here –

Key players in 2021 are engaged in several strategic initiatives includingmergers & acquisitions, collaborations, joint ventures, partnership agreements, research & developments, product modifications, technological advancements, upgradations etc to lead the market. Innovative launches to create distinction is the most profitable strategy in 2021.

For instance, Otsuka Corporation has been conducting a research since the last two year to develop and introduce next-generation tuberculosis drug candidate called OPC-167832. In 2021, the drug is undergoing initial trials in South Africa to confirm its safety and efficacy throughout the world.

OPC-167832 is believed to kill tuberculosis bacteria through a mechanism that inhibits the activity of enzymes that are essential for synthesizing mycobacterium tuberculosis cell walls.

The mechanism of this drug completely differs from the existing TB drugs including Deltyba. The company is still engaged in tuberculosis R&D to establish innovative treatment methods. Such innovative introductions are leading to create a strong position of the company among the customers.

On the other hand, Danaher Corporation developed new rapid molecular test for tuberculosis on July, 2020 called as ‘Xpert MTB/ XDR’ test which enables expanded drug resistance TB profiling in less than 90 minutes. This test enables the clinicians to quickly prescribe treatment regimens for extensively drug-resistent TB (XDR-TB).

The test is resisant to multiple first and second-line TB drugs and is currently filling a critical gap that is jeopardizing global TB targets. In 2020, company continued to invest in research activities despite major losses suffered due to the pandemic.

According to a recent report given by World Health Organisation in 2020, the growing number of tuberculosis cases are from Asia Pacific which is surging the growth of this market.

Asia Pacific is dominating the global market for tuberculosis biomarkers in 2021 on account of rising cases of tuberculosis among people as well as presence of leading manufacturers in this market.

To receive extensive list of important regions, ask for TOC here –

Tuberculosis Biomarkers Market: Snapshot

Tuberculosis (TB) biomarkers occupy a central role in the disease characterization, infection and risk assessment, rapid diagnosis, and ultimately cure. Despite considerable volumes of research and the proliferation of biomarker candidates over the past decades, the global market is still characterized by large unmet needs. This is evident in the devastating effect of tuberculosis on the mortality and morbidity in worldwide populations.

The market is replete with tuberculosis biomarkers that claim to measure the status of infection and further predict outcomes of vaccination or therapy. But, the fact that none of them is efficacious enough to enable a simple, accurate, and rapid diagnostic test for the infectious disease is a pressing concern.

The development of biomarkers that can measure responsiveness to treatments and those that assess the risk of developing into full-fledged disease are critical clinical endpoints.

Hence, the development and launch of biomarkers that can measure well against such clinical endpoints is the need of the hour, belittling the massive investments made by companies so far. Hence, there is a need for more research that looks into reducing the gap between an emerging panoply of biomarker candidates and their efficacy against targeting product profiles.

The need for non-DNA biomarkers to achieve this goal could unlock new, exciting avenues in the tuberculosis biomarkers market.

Tuberculosis is a major dilemma in low and middle- income countries, accounting for second leading cause of death from an infectious disease, globally. The diagnosis of tuberculosis is crucial for controlling the disease. Biomarkers are biological markers which measure and asses as an indicator of normal biological states, pathogenic process, pharmacological responses and future disease risk of patients.

The tuberculosis biomarkers can help classify patients at a single time point having active tuberculosis, latent M. tuberculosis or no diseases. In addition, these biomarkers have potential to predict future reactivation risk, support monitoring of the diseases and support in development of new drugs for tuberculosis.

Scientists are exploring more about the tuberculosis biomarkers for accurate, cost effective and rapid diagnostic assay for better predictive of tuberculosis treatment outcome.

For critical insights on this market, request for methodology here –

In 2015, Spring Meeting of the Biomarkers and Correlates Working Group (BCWG), tuberculosis experts from around the world, discussed and made recommendations for the TB vaccine community regarding the studies needed to better define biomarkers or correlates for risk of TB infection or disease.

Furthermore, there has been an increase in investment of tuberculosis research which have help address shortcomings in tuberculosis biomarkers research and development.

For instance, in 2012 The Bill & Melinda Gates Foundation announced $7.7 million funding for 10 new grants to identify biomarkers for diagnosing tuberculosis (TB). Thus, increase in investment and rising research and development activities associated with the tuberculosis biomarkers is anticipated to create new opportunities for the market, during the forecast period market.

Tuberculosis Biomarkers Market: Segmentation

Segmentation based on Type

  • Immune response-based tests
  • Serologic and antigenic biomarkers
  • NAAT
  • Others

Segmentation based on End User

  • Research Institutes
  • Diagnostic laboratories
  • Pharmaceutical Industry
  • Government Institutes

Segmentation by Application

  • Drug Discovery and Research / Clinical Trails
  • Diagnostics
  • Disease Prognosis

Tuberculosis biomarkers Market: Key Participants

Key players in the tuberculosis biomarkers market are Antrum Biotech, QIAGEN, Thermo Fisher Scientific, QuantuMDx, bioMérieux, Abbott, Rapid Biosensor Systems Ltd, GlobalBio Diagnostics Corp., Danaher Corporation, Alere Inc and Cisbio Bioassays.

Pre-Book Right Now for Exclusive Analyst Support –

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Matched content

Editor’s pick

Express Press Release Distribution